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STUDY PROTOCOL Open Access
Intranasal fentanyl versus intravenous morphine
in the emergency department treatment of
severe painful sickle cell crises in children: Study
protocol for a randomised controlled trial
Michael Joseph Barrett1,2,3, John Cronin1,2, Adrian Murphy1,2, Siobhan McCoy1,2, John Hayden2,
SinéadNic an Fhailí2, Tim Grant4, Abel Wakai5, Corrina McMahon6, Sean Walsh1,2 and Ronan O’Sullivan1,2,3*
Abstract
Background: Children with sickle cell disease (SCD) frequently and unpredictably present to the emergency
department (ED) with pain. The painful event is the hallmark acute clinical manifestation of SCD, characterised by
sudden onset and is usually bony in origin. This study aims to establish if 1.5mcg/kg of intranasal fentanyl
(INF; administered via a Mucosal Atomiser Device, MAD™) is non-inferior to intravenous morphine 0.1 mg/kg in
severe SCD-associated pain.
Methods/design: This study is a randomised,double-blind, double-dummy active control trial of children (weighing
more than 10 kg) between 1 year and 21 years of age with severe painful sickle cell crisis. Severe pain is defined as
rated seven or greater on a 0 to 10 age-appropriate numeric pain scale or equivalent. The trial will be conducted in
a single tertiary urban paediatric ED in Dublin, Ireland. Each patient will receive a single active agent and a single
placebo via the intravenous and intranasal routes. All clinical and research staff, patients and parents will be blinded
to the treatment allocation. The primary endpoint is severity of pain scored at 10 min from administration of the
study medications. Secondary endpoints include pain severity measured at 0, 5, 15, 20, 30, 60 and 120 min after the
administration of analgesia, proportion of patients requiring rescue analgesia and incidence of adverse events. The
trial ends at 120 min after the administration of the study drugs. A clinically meaningful difference in validated pain
scores has been defined as 13 mm. Setting the permitted threshold to 50% of this limit (6 mm) and assuming both
treatments are on average equal, a sample size of 30 patients (15 per group) will provide at least 80% power to
demonstrate that INF is non-inferior to IV morphine with a level of significance of 0.05.
Discussion: This clinical trial will inform of the role of INF 1.5mcg/kg via MAD in the acute treatment of severe
painful sickle cell crisis in children in the ED setting.
Trial registration: Current Controlled Trials ISRCTN67469672 and EudraCT no. 2011-005161-20
Keywords: Sickle cell disease, Paediatric, Pain, Analgesia, Intranasal, Fentanyl, Randomised Controlled Trial,
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Background
Children with sickle cell disease (SCD) frequently and
unpredictably present to the emergency department
(ED) [1]. In these children, pain is a common experi-
ence, beginning as early as 4 to 6 months of age [2].
These painful episodes (often referred to as a pain “cri-
sis”) are the hallmark acute clinical manifestation of
SCD, characterised by the sudden onset of pain. Al-
though pain is a dominant feature in the medical lives of
children with SCD, with approximately 70% of their hos-
pitalisations after ED presentation being for uncon-
trolled pain [1-3], it is often under-recognised and
undertreated [4-6]. Unrelieved pain does not only have
negative consequences, such as missed days of school,
restriction of other activities, and fear or mistrust of
health care providers, but also can lead to amplified re-
sponses to subsequent pain experiences and sensitivity
to pain later in life [2,7]. Furthermore, frequent painful
episodes are associated with early mortality in patients
with SCD [3,8].
Suboptimal acute pain management in SCD patients
is associated with caregivers' preoccupation with the
pathophysiological causes of vaso-occlusion and concern
of creating opioid dependence [9], and a negative atti-
tude toward patients with SCD in urban hospitals and
EDs [5,9-11]. The truth regarding opiate addiction in
patients with SCD is markedly less dramatic than con-
ventional opinion would suggest. Prevalence estimates
for opiate addiction among patients with SCD range from
0.5% to 8% compared to patients with other chronic
pain syndromes with opiate addition rates of 3% to 16%
[9,12,13]. Two putative biological mechanisms may ex-
plain the relatively low prevalence of opiate addiction
among SCD patients. First, the allelic variants in the genes
involving the opioid (UGT2B7, OPRM1, and ABCB1
genes) and non-opioid system (COMT gene) can alter
the efficacy of morphine in SCD patients [14,15]. Second,
the pharmacokinetics of morphine is altered in SCD
patients, with clearance of morphine being 3–10 fold
higher in SCD patients compared with healthy non-SCD
patients [16].
Although treating acute painful sickle cell crisis
(PSCC) with appropriate potent analgesia [intravenous
(IV) and/or oral controlled-release morphine] is humane
and reduces the length of hospitalisation in SCD patients
with mild to moderate pain [17], the evidence base for
acute ED pain management in children with PSCC is
limited [18]. Alternative, quicker and pain-free methods
of providing safe and effective analgesia include the
intranasal (IN) route for the administration of opiates
such as fentanyl, sufentanil and diamorphine [19-35].
The IN route is increasingly being used for the safe
administration of analgesia in paediatric patients with
painful conditions (e.g. burns, long bone fractures and
post-operatively) [24,26,28,34,35]. In the emergency care
setting, IN fentanyl is also currently used for managing
pain in children in the pre-hospital setting [36,37]. Com-
pared with other routes of drug administration, the IN
route has unique advantages that may allow for more ef-
ficient use of resources, more rapid pain relief, and
higher patient and provider satisfaction [38,39]. The
highly vascularised nasal mucosa and the olfactory tissue
in direct contact with the central nervous system permit
rapid drug absorption, high bioavailability and onset of
action comparable with IV drug administration [39]. Fur-
thermore, IN drug administration is also relatively pain-
less, inexpensive, convenient and easy to deliver with
minimal training [39]. Fentanyl is a potent opioid (ap-
proximately 100 times more potent than morphine) with
high bioavailability and a short duration of action (IN
fentanyl plasma half-life of 1 h). When used in analgesic
doses, fentanyl results in minimal sedation and little
haemodynamic instability [40].
The primary aim of this study is to determine if
1.5mcg/kg of intranasal fentanyl via a Mucosal Atomiser
Device (MAD™) is non-inferior to intravenous morphine
in children presenting with severe pain associated with
SCD.
Methods/design
Study aims
To determine whether 1.5mcg/kg IN fentanyl is non-
inferior to 0.1 mg/kg IV morphine in the management
of severe pain in children with PSCC.
Study design and setting
This is a randomised, double-blind, double-dummy, ac-
tive control clinical trial. It will be conducted at a single
tertiary urban paediatric ED (Our Lady’s Children’s Hos-
pital Crumlin (OLCHC)) in Dublin, Ireland.
Subject selection
Children satisfying the screening inclusion and exclusion
criteria, and the randomisation inclusion and exclusion
criteria (Table 1), who present to the recruiting ED dur-
ing the study period will be eligible for recruitment into
the trial.
Definition of painful crisis
An episode of severe pain is defined as the occurrence
of pain in the extremities, back, abdomen or chest due
to sickle-cell disease that is rated 7 or greater on a 0–10
numeric pain scale or equivalent [8].
Inclusion and exclusion criteria
Inclusion and exclusion criteria are presented in Table 1.
Barrett et al. Trials 2012, 13:74 Page 2 of 7
http://www.trialsjournal.com/content/13/1/74
Patient randomisation
Patients who fulfil the randomisation eligibility criteria
and whose parents provide informed consent will be
randomised to receive intranasal fentanyl and intraven-
ous placebo or intranasal placebo or intravenous mor-
phine. The randomisation process was designed by
CSTAR (Health Research Board Centre for Support and
Training in Analysis and Research). Trial randomisation
codes will be generated by CSTAR. The randomisation
process provides a random allocation of 30 subjects be-
tween the two treatment groups. Randomisation will be
on an individual basis using a computer-generated block
randomisation. The randomisation is not stratified.
Randomisation treatments
All study drugs will be packaged in blinded trial packs
by a clinical trial pharmacist who is blinded to interven-
tions and outcomes. Both fentanyl and morphine are
controlled drugs. The Misuse of Drugs Acts, 1977 and
1984, and the Misuse of Drugs Regulations, 1988, 1993
and 2007, determine the conditions of production, pos-
session, supply, importation and exportation of con-
trolled drugs. Standard operating procedures (SOPs) are
developed for every stage of a controlled drug’s journey
from procurement (ordering, receipt and transport), safe
storage, supply, administration, destruction and guidance
for dealing with an incident. SOPs will be accessible to
staff at all times.
Fentanyl and matched-placebo
Fentanyl citrate 50 μg/ml (Sublimaze, Marketing Au-
thorisation No. PA 0748/044/001) is manufactured by
Janssen Cilag, Ltd., and is an authorised product in Ire-
land. However, fentanyl is licensed for usage for paediat-
ric pain via the intravenous route but not via the
intranasal route. The matched size and shape of the pla-
cebo ampoule is necessary to maintain blinding of inter-
vention by the investigators. The matched placebo for
intranasal fentanyl is a 2-ml water for injection BP glass
ampoule by Hamelyn Pharmaceuticals. The product is
licensed in the UK for dissolving and diluting drug sub-
stances (reference no. PL 01502/0003R).
Morphine and matchedplacebo
Morphine sulphate 10 mg/ml BP is manufactured by
Antigen Pharmaceuticals and authorised in Ireland
(Marketing Authorisation No.PA 73/20/1). The matched
placebo for intravenous morphine is a 1-ml water for in-
jection glass ampoule by Roche Pharmaceuticals. It is an
authorised product in Ireland for dilution of Clonazepam
ampoules.
Overdosage considerations
In the considered event of an overdosage of opioid the
approach of risk mitigation is as follows:
1. Trial pack manufacture Standard Operating
Procedures;
2. Dispensing Standard Operating Procedures;
3. Monitoring of patient vital signs and clinical signs of
opiate toxicity;
4. ED Staff training; and
5. Consideration of antidotal/reversal treatment
(Naloxone is a standard stocked drug in the ED).
Study procedure
Dose and administration schedule
The study drugs will be administered at time 0 as out-
lined in the study flow chart (Figure 1). The patient’s
age-appropriate pain score will be recorded at time
points 0, 5, 10, 15, 20, 30, 60 and 120 min by a single in-
vestigator on the patient’s case report form. After the
end of the 120 min the study will be terminated. The Faces,
Legs, Activity, Cry, Consolability (FLACC) scale and
Manchester Pain Ruler will be used as age-appropriate
pain scales for pre-verbal/early verbal children and older
verbal children respectively.
Table 1 Inclusion and exclusion criteria
Inclusion criteria:
• Ages 1 – 21 years
• ≥10 kg and ≤70 kg
• Known sickle cell disease presenting with severe pain
• Written informed consent, ideally from both parents
(and assent, where appropriate), obtained prior to painful
crisis (for example, in Haematology clinic)
• Verbal consent (and assent, where appropriate)
obtained at the time of the painful crisis in the ED
• Hospital admission required for painful crisis
Exclusion Criteria:
• Patient has received parenteral narcotic analgesic within
4 hours of ED presentation
• Oxygen saturations below 95% on initial assessment
• Altered conscious state as defined by a Glasgow
Coma score less than 15
• Contraindications to fentanyl/morphine usage
• Inability to secure IV access
• Patient has participated in another clinical trial
involving an Investigation Medicinal Product (IMP) within
4 weeks of dosing, or is currently enrolled in another
clinical trial involving an IMP, or has been previously
enrolled in this trial
• Patients who have any condition that would make
him/her, in the opinion of the Investigator or Sponsor,
unsuitable for the study, or who are, in the opinion of the
Investigator, not likely to complete the study for any reason
• Blocked or traumatised nose
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Outcome measures
The primary outcome measure is severity of pain as
measured using a validated pain score at 10 min post-
analgesia.
The secondary outcome measures are:
 Severity of pain as measured by pain scores at 0, 5,
15, 20, 30, 60 and 120 minutes after the
administration of analgesia;
 The proportion of patients requiring rescue opioid
analgesia; and
 Adverse events within the 120 minutes study period.
Sample size, power and statistical methods
The purpose of this study is to establish non-inferiority
in pain relief for IN fentanyl as compared to IV mor-
phine in the ED treatment of severe painful sickle cell
crises in children. The study is a repeated measures
study, measuring pain scores before and after the treat-
ment. A detailed statistical analysis plan has been devel-
oped in association with CSTAR. From a previous study
it is estimated that the reduction in pain will be 26 mm
on a visual analogue score (VAS) with a standard devi-
ation of 6 mm [27]. As a non-inferiority study, a thresh-
old of how different the two treatments are has to be
established, generally from clinical data. A clinically
meaningful difference in VAS scores has been defined as
13 mm [41,42]. Setting the allowable threshold to 50% of
this limit (6 mm) and assuming the two treatments are
on average equal, a sample size of 30 patients (15 per
group) will provide at least 80% power to demonstrate
that INF is non-inferior to IV morphine with a level of
significance of 0.05.
Data analysis
Non-inferiority of the intranasal fentanyl treatment will
be established based on a repeated-measure analysis of
variance (ANOVA) with time of measurement (before
or after treatment) as the within-subjects factor and
treatment as the between-subjects factor. Data will be
analysed on an intention-to-treat and a per protocol
basis.
Discussion
Ethical considerations
This study is to be performed in accordance with the
GoodClinical Practice (GCP)Guidelines, theEUCTDirec-
tive 2001/20.EC, GCP Commission Directive 2005/28/EC,
the Declaration of Helsinki (2008) and all other local
regulatory requirements. Risk analysis was carried out as
part of protocol development. The study protocol was
approved by the institutional Health Research Ethics
Committee (HREC), OLCHC, Dublin. Patients will be first
screened and consented/assented in the Haematology
Outpatient Department and upon arrival in the ED, and
upon meeting the study eligibility criteria will be verbally
re-consented/assented in the ED.
Regulatory considerations
The Irish Medicines Board (IMB) is the competent au-
thority for the review and approval of clinical trials with
an investigational medicinal product in Ireland. The ap-
plication process for a medicinal trial was successful
after formal engagement with the IMB prior to applica-
tion and during the application process. IMB approval
for this trial was granted on 20 January 2012.
Active IV morphine
Dummy intranasal
Potential patient presents at ED triage
Eligibility assessed and verbal consent with or without assent confirmed
Double blind randomisation
Active intranasal fentanyl
Dummy IV
Primary outcomes Pain
Scores at 10 minutes
Secondary outcomes
to 120minutes
Usual ED care
Written Consent/Assent prior to painful crisis
Figure 1 Study flow chart. The schedule of study observations that will be recorded during the 120-min observation period.
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Breaking of the study blind
During the study
If an adverse event is regarded as a potential serious un-
expected suspected adverse reaction (SUSAR) by the
sponsor, the treatment group to which the trial subject
affected belongs is unblinded for that subject alone. The
procedure will ensure that the identity of the IMP is only
revealed as far as necessary (GCP Directive). All staff
will have received training on all aspects of the trial
protocol prior to commencement of the trial.
The principal investigator (PI) or authorised member
of the team will have a written procedure for requesting
randomisation codes for rapidly identifying a blinded
IMP in an emergency. Breaking the blind of a trial sub-
ject will be at the discretion of the PI, when clinically
indicated for the safety of the patient or in the event of a
SUSAR. If the patient needs to be unblinded we will refer
to the unblinding SOP for complete details of the proce-
dures to be followed. The master randomisation codes
will be kept by the clinical trial pharmacist and the PI.
Unblinding will be performed by the senior clinician/
pharmacist when the criteria for a serious adverse event
(SAE)/SUSAR have been met, and there is a necessity for
the PI or treating healthcare professional to know which
treatment the patient is receiving to ensure that the pa-
tient receives appropriate urgent safety measures.
A 24-h contact number will be available in the circum-
stances when unblinding is required. The scenario will
be communicated and when the unblinding criteria are
met the unblinding will ensue. The PI will document the
breaking of the code, and the reasons for doing so, in
the site file and in the patient’s medical notes, and in ac-
cordance with the clinical trial protocol.
Following completion of the study
Study unblinding will only take place once the statistical
analysis plan has been agreed upon by the trial team and
the final database locked.
Bias and confounding variables
In terms of selection bias, we feel that this study targets
a patient population to whom this research ultimately
will be clinically applicable and valuable. Every effort will
be made to ensure that recruitment of participants oc-
curs over all 24-h periods (including weekends) by hav-
ing patients recruited by the ED physician treating the
patient and consented at haematology outpatients in
advance of a PSCC or as an inpatient in OLCHC in an-
ticipation of their next crisis. We anticipate that the
randomised, double-blinded, controlled design of this
study will minimise the effect of confounding variables
on our analysis.
Safety reporting
All adverse events that occur during the study period
observed by one of the clinical staff, or reported by the
patient or parent/guardian spontaneously, or in response
to a direct question, will be noted on the appropriate
form [i.e. adverse event (AE), SAE or SUSAR form].
These forms are de-identified. The following procedures
will take place depending on the type of event that has
occurred.
Adverse event (AE)
Each AE will be recorded by a member of the research
team on an AE form. Adverse events will be classified
on the form in terms of their severity, association with
the study drug, expectedness and seriousness. They will
be recorded on an adverse event log. The adverse events
will be reported to the sponsor and the institutional
HREC on a yearly basis as part of an annual safety report
and at the end of the trial.
Serious adverse event (SAE)
Each SAE will be recorded by a member of the research
team on an SAE form. SAEs will be classified on the
form in terms of their severity, relatedness to the study
drug and expectedness. They will be recorded on aser-
ious adverse event log. All SAEs will be reported on the
SAE form within 24 h to the sponsor and the institu-
tional HREC. The research team will ensure that follow-
up information and a detailed written report are pro-
vided when available. An ongoing prospective study of
children experiencing severe painful sickle cell crisis in
our ED reveals that over 90% of these children are ad-
mitted as an inpatient for further management of their
crisis. This, therefore, would not be truly indicative of an
SAE in this cohort of patients and will not be classified
as such.
Suspected unexpected serious adverse drug reactions
(SUSAR)
Each SUSAR will also require expedited reporting to the
sponsor. This will occur as soon as possible, but no later
than 24 h after a member of the research team has first
knowledge of the minimum criteria for expedited report-
ing. In each case, relevant follow-up information will be
sought and a detailed, written report completed as soon
as possible. The sponsor has responsibility to ensure all
relevant and available information is forwarded to the
competent authority (Irish Medicines Board) and the ap-
propriate health ethics committee (HREC, OLCHC). For
fatal or life-threatening events this will be done as soon
as possible and not later than 7 days after the sponsor
becomes aware of the event. Additional relevant infor-
mation will be sent within 8 days of the first report. This
will be sent no later than an additional 15 calendar days.
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For AEs that are not fatal or life-threatening, the spon-
sor will ensure that a SUSAR is reported as soon as pos-
sible and in any event not later than 15 days after the
sponsor is first aware of the event.
The parents of participants will be provided with 24-h
contact details of a study representative if they have con-
cerns about any component of the study or their child’s
condition. We will also report to the hospital (OLCHC)
Risk Management Team and the Drugs Advisory Com-
mittee of the study site.
Trial status
Recruitment commenced in April 2012 for the 30 pa-
tients needed for the study. It is anticipated patient re-
cruitment will be completed by early 2013.
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